Medicus Pharma (MDCX) Non-Current Assets (2024 - 2025)
Medicus Pharma (MDCX) posted Non-Current Assets of $170733.0 for Q4 2025, down 13.0% quarter-over-quarter from $196249.0 in Q3 2025, and down 36.43% year-on-year from $268571.0 in Q4 2024.
Medicus Pharma (MDCX) Non-Current Assets (2024 - 2025) Analysis & Trends
Medicus Pharma (MDCX) has reported Non-Current Assets for 2 consecutive years, with $170733.0 the latest figure, recorded in Q4 2025.
- Non-Current Assets for Q4 2025 came in at $170733.0, down 36.43% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.9 million (changed N/A YoY), and the FY2025 annual result was $170733.0, down 36.43% from the prior year.
- Non-Current Assets was $170733.0 for Q4 2025 at Medicus Pharma, down from $196249.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $937897.0 in Q2 2025 and troughed at $170733.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 61.74 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 141.72 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 102.93 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | 84.40 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 125.00 Mn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 61.03 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 37.64 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 165.18 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Medicus Pharma | 6.91 Mn | -1.69 Mn | - | 170,733.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 170,733.00 |
| Sep 30, 2025 | 196,249.00 |
| Jun 30, 2025 | 937,897.00 |
| Mar 31, 2025 | 570,091.00 |
| Dec 31, 2024 | 268,571.00 |